Results 151 to 160 of about 5,026 (198)

Assessment of Telisotuzumab Vedotin Drug-Drug Interaction Potential Using Physiologically-Based Pharmacokinetic Modeling and Simulations. [PDF]

J Clin Pharmacol
Riad MMH, Brunsdon P, Menon R, Marroum P, Parikh A.   +4 more
europepmc   +1 more source

Vascular endotelial growth factor plasma concentrations before and after intervitreal injection of bevcizumab and ranibizumab [PDF]

, 2012
João Pedro Vieira Fonseca
core  

Successful Birth After First-Trimester Ravulizumab Exposure in a Patient With Paroxysmal Nocturnal Hemoglobinuria: A Case Report. [PDF]

EJHaem
Morioka T, Arai S, Arai Y, Konno S, Tokuda K, Matsuo T, Matsumoto K, Shirasaki R, Ooi J, Kihira C, Sasamori Y, Nagasaka K, Tashiro H.   +12 more
europepmc   +1 more source

Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. [PDF]

Biomedicines
Mansour GK, Alangari L, Khosyfan L, Alhammad R, Hajjar AW.   +4 more
europepmc   +1 more source

Antibody glycosylation in neuroimmune diseases. [PDF]

J Transl Med
Li K, Luo M, Xu L, Ouyang Y, Zhou Q, Xiang W, Ren Y, Wen Z, Shi G, Luo Z, Yang H.   +10 more
europepmc   +1 more source

Intracellular interaction between FcRY receptor and IgY in ovarian vascular endothelial cells during avian maternal IgY transfer. [PDF]

Poult Sci
Okamoto M, Furukawa K, Mizushima S, Murai A.   +3 more
europepmc   +1 more source

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. [PDF]

Cells
Yasui H, Idogawa M, Ishida T, Imai K.
europepmc   +1 more source

Dulaglutide and pregnancy: a comprehensive safety assessment using the <i>ex vivo</i> placenta perfusion and <i>in vitro</i> models. [PDF]

Front Pharmacol
Kuoni S, Caviglia S, Dolder A, Gawinecka J, Ochsenbein-Kölble N, Simões-Wüst AP.   +5 more
europepmc   +1 more source

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys [PDF]

Journal of Pharmaceutical Sciences, 2019
There is a growing interest in developing inhibitors of the neonatal Fc-receptor, FcRn, for use in the treatment for humoral autoimmune conditions. We have developed a new physiologically based pharmacokinetic model that is capable of characterizing the pharmacokinetics and pharmacodynamics of anti-FcRn monoclonal antibodies (mAb) in mice, rats, and ...
Joseph P Balthasar
exaly   +3 more sources